Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Decision brief
Answer first · skim in under a minute
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
Gilead’s bulevirtide finally cleared the U.S. bar: on May 22, 2026 the FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) 8.5 mg for adults with chronic hepatitis D, making it the first FDA-approved HDV therapy and resetting competitive clocks for Bay Area follow-ons still in development.
Contents11 sections
Key Takeaways
- FDA accelerated approval: May 22, 2026 for Hepcludex (bulevirtide-gmod) 8.5 mg once daily (Business Wire).
- Indication: chronic HDV in adults without cirrhosis or with compensated cirrhosis.
- Core evidence: Phase 3 MYR301 (NCT03852719); Week 48 combined response beat delayed treatment.
- Accelerated pathway: continued approval may require confirmatory clinical-outcome data.
What exactly did the FDA approve for bulevirtide?
According to Gilead’s May 22, 2026 Business Wire release, Hepcludex is indicated for chronic HDV infection in adults without cirrhosis or with compensated cirrhosis.
The product is a once-daily subcutaneous injection at 8.5 mg. The company framed it as the first and only FDA-approved HDV treatment in the United States.
How strong is the MYR301 evidence package?
Accelerated approval rested on reductions in HDV RNA and ALT normalization, primarily from Phase 3 MYR301. Gilead said Week 48 showed a statistically significant improvement in combined virologic and biochemical response versus delayed treatment.
ClinicalTrials.gov NCT03852719 lists MYR301 as completed with 150 participants enrolled. That registry record is the cleanest public check on study identity and size.
Gilead’s own labeling language is explicit: improvement in disease-related clinical outcomes has not been established, and continued approval may depend on confirmatory trials.
How does U.S. approval relate to Europe’s Hepcludex history?
Hepcludex was already an authorized European medicine for chronic HDV with compensated liver disease. The EMA Hepcludex EPAR remains the primary European reference for earlier authorization and product information.
- EU: earlier market access for bulevirtide in HDV.
- U.S.: May 22, 2026 accelerated approval closes the access gap.
- Dose and branding in U.S. communications: Hepcludex 8.5 mg (bulevirtide-gmod).
- Safety watchpoint in U.S. PI summaries: posttreatment severe acute exacerbation of hepatitis D and B.
What should Bay Area competitors infer from this decision?
A first-in-class FDA label raises the evidentiary bar for later entrants. Rival programs must show differentiation on durability, cirrhosis stage coverage, combination regimens, or outcomes endpoints that accelerated approval deferred.
Company names in Bay Area HDV pipelines remain commercially relevant, but their trial readouts should be tracked on ClinicalTrials.gov and sponsor wires—not inferred from Gilead’s approval alone.
How should analysts model the commercial and regulatory risk?
Start with the accelerated-approval contingency: confirmatory benefit must still be shown. Then model adult HDV prevalence carefully; global estimates often cited around 12 million people with HDV coinfection are epidemiology context, not a U.S. treated-patient forecast.
Access, prior authorization, and specialist prescribing will decide near-term uptake more than the “first approved” headline.
What remains unproven after the bulevirtide nod?
The FDA decision does not prove that bulevirtide improves hard clinical outcomes such as decompensation, transplant, or death. It also does not settle combination strategies with pegylated interferon or oral antivirals for every patient subgroup.
Until confirmatory data post, treat the U.S. label as a biomarker-driven accelerated approval with an open evidence debt.
What practical steps should BD teams take this quarter?
Update HDV competitive maps with the May 22, 2026 U.S. approval date and the 8.5 mg once-daily dose. Flag the confirmatory-trial contingency in every forecast tab that previously treated U.S. approval as binary certainty.
Re-read EMA’s Hepcludex EPAR beside the U.S. Business Wire release so EU label history does not get confused with the new U.S. accelerated pathway. Keep NCT03852719 bookmarked for enrollment and design checks when comparing rival HDV assets.
Finally, separate “first approved” messaging from outcomes claims. The approval text itself warns that clinical-outcome improvement is not established yet.
Related NovaPharma coverage
Frequently Asked Questions
When did the FDA approve bulevirtide for HDV?
On May 22, 2026, Gilead announced FDA accelerated approval of Hepcludex (bulevirtide-gmod) 8.5 mg for adults with chronic hepatitis delta virus infection without cirrhosis or with compensated cirrhosis.
What evidence supported the Hepcludex U.S. approval?
Accelerated approval was based mainly on Phase 3 MYR301 (NCT03852719), which showed a statistically significant Week 48 combined virologic and biochemical response versus delayed treatment. Improvement in disease-related clinical outcomes has not been established.
Was Hepcludex already authorized in Europe?
Yes. The EMA Hepcludex EPAR records European authorization for bulevirtide in chronic HDV with compensated liver disease, so the May 2026 U.S. decision closed a long U.S.–EU gap rather than creating a first global authorization.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for bulevirtide.
Unlock full calendar →Gilead Sciences pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
